RG
ORKA

Redmile Group’s Oruka Therapeutics ORKA Stock Holding History

Redmile Group’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-386,963
Closed -$3.97M – 57
2025
Q1 		$3.97M Sell
386,963
-24,765
-6% -$309K 0.38% 41
2024
Q4 		$7.98M Hold
411,728
– – 0.56% 38
2024
Q3 		$10.1M Buy
+411,728
New +$14.3M 0.59% 39

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Redmile Group's ORKA Position: Q2 2025 in Review

Redmile Group sold out of Oruka Therapeutics (ORKA) in Q2 2025, closing a stake of 386,963 shares — an estimated $3.97M sold.

Redmile Group first reported a position in ORKA in Q3 2024 and held it in 3 quarters. The position peaked at $10.1M in Q3 2024. 81 funds tracked by Wall St. Rank hold ORKA as of Q2 2025.

  • Redmile Group reported no remaining Oruka Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Redmile Group sold 386,963 Oruka Therapeutics shares in Q2 2025, an estimated $3.97M.
  • Redmile Group first reported a position in Oruka Therapeutics in Q3 2024 and held it in 3 quarters.
  • Redmile Group's Oruka Therapeutics position peaked at $10.1M in Q3 2024.
  • 81 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2025.

Based on Redmile Group's 13F filing for Q2 2025, filed 14 Aug 2025.